1
|
Zhang M, Yuan Y, Gao Y, Lu R, Deng Y. The effectiveness of Salvianolate injection for in-stent restenosis after percutaneous coronary intervention: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2022; 101:e29153. [PMID: 35482985 PMCID: PMC9276184 DOI: 10.1097/md.0000000000029153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Accepted: 03/07/2022] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND In-stent restenosis (ISR) caused by vascular remodeling after percutaneous coronary intervention limits the long-term efficacy of this method. Salvianolate injection is now widely used in the clinical treatment of ISR. However, there is no systematic review or meta-analysis to evaluate the effects of Salvianolate injection on ISR. METHODS We will search articles in 8 electronic databases, including the Cochrane Central Register of Controlled Trials, PubMed, Embase, the Web of Science, China National Knowledge Infrastructure, the Chinese Biomedical Literature Database, Wanfang Database, and the Chinese Scientific Journal Database for randomized controlled trials of ISR treated by Salvianolate injection from their inception to February 27, 2022. The primary outcome measure will be the restenosis rate. The data meeting the inclusion criteria were analyzed by RevMan V.5.4 software. Two authors evaluated the study using the Cochrane collaborative risk bias tool. We will use a scoring method to assess the overall evidence supporting the main results. RESULTS This study will analyze the clinical effectiveness of Salvianolate injection in the treatment of ISR. CONCLUSION The findings of this systematic review will provide evidence to evaluate the effectiveness of Salvianolate injection for the treatment of ISR. INPLASY REGISTRATION NUMBER INPLASY202220117.
Collapse
Affiliation(s)
- Miao Zhang
- Doctor of Medicine, School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China
| | - Yue Yuan
- Doctor of Medicine, School of Basic Medicine, Changchun University of Chinese Medicine, Changchun, China
| | - Ying Gao
- Doctor of Medicine, School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China
| | - Ruozhu Lu
- Doctor of Medicine, School of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China
| | - Yue Deng
- Affiliated Hospital, Changchun University of Chinese Medicine, Changchun, China
| |
Collapse
|
2
|
Kumar R, Batra MK, Khowaja S, Ammar A, Kumar A, Shah JA, Sial JA, Saghir T, Karim M. CHA 2DS 2-VASc, a Simple Clinical Score Expanding Its Boundaries to Predict Contrast-Induced Acute Kidney Injury After Primary Percutaneous Coronary Interventions. Int J Nephrol Renovasc Dis 2022; 14:495-504. [PMID: 35002286 PMCID: PMC8725833 DOI: 10.2147/ijnrd.s347303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Accepted: 12/09/2021] [Indexed: 11/29/2022] Open
Abstract
Objective Promising results of CHA2DS2-VASc score have been reported for the prediction of contrast-induced acute kidney injury (CI-AKI) after percutaneous coronary intervention (PCI). However, data of its predictive strength in the context of primary PCI are not available. Therefore, in this study, we have assessed predictive value of CHA2DS2-VASc score for CI-AKI after primary PCI. Methods This analytical cross-sectional study was conducted between January 2021 and June 2021 at the National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan. Inclusion criteria of the study was consecutive adult patients who had undergone primary PCI. Baseline CHA2DS2-VASc score was calculated, and either a 25% or 0.5 mg/dL increase in post-procedure serum creatinine level as compared to baseline level was categorized as CI-AKI. Results A total of 691 patients were included, of which 82.1% (567) were male. CI-AKI after primary PCI was observed in 63 (9.1%) patients, out of which 66.7% (42) of patients had CHA2DS2-VASc score of ≥2. The area under the curve (AUC) for the score was 0.725 [0.662 to 0.788] with a sensitivity and specificity of 66.7% [63.1% to 70.2%] and 66.7% [53.7% to 78.1%], respectively, at a cut-off value of ≥2. In multivariable analysis, left ventricular ejection fraction ≤30% and CHA2DS2-VASc ≥2 were found to be independent predictors with adjusted odds ratios of 2.19 [1.06–4.5] and 2.13 [1.13–4.01], respectively. Conclusion CHA2DS2-VASc score has a good predictive value for the prediction of CI-AKI after primary PCI. Criteria of CHA2DS2-VASc ≥2 can be used for the risk stratification of CI-AKI after primary PCI.
Collapse
Affiliation(s)
- Rajesh Kumar
- Adult Cardiology Department, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
| | - Mahesh Kumar Batra
- Adult Cardiology Department, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
| | - Sanam Khowaja
- Adult Cardiology Department, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
| | - Ali Ammar
- Adult Cardiology Department, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
| | - Ashok Kumar
- Adult Cardiology Department, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
| | - Jehangir Ali Shah
- Adult Cardiology Department, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
| | - Jawaid Akbar Sial
- Adult Cardiology Department, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
| | - Tahir Saghir
- Adult Cardiology Department, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
| | - Musa Karim
- Research Department, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
| |
Collapse
|
3
|
Li Z, Luan Y, Wang M, Li Y, Shen X, Fu G, Zhang W. Effects of salvianolate on microcirculatory disturbance in patients with stable coronary heart disease: study protocol for a randomized controlled trial. Trials 2021; 22:192. [PMID: 33685500 PMCID: PMC7938457 DOI: 10.1186/s13063-021-05099-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2020] [Accepted: 02/05/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Obstruction of coronary microcirculation can lead to myocardial ischemia and poor prognosis. Salvianolate exerts cardiovascular protection at cellular levels. However, no studies have confirmed the effect of salvianolate on stable coronary heart disease (CHD) with high fractional flow reserve (FFR) and myocardial microcirculatory disturbances. METHODS/DESIGN This study will enroll 78 patients who have stable coronary disease with 50 to 70% stenosis in major coronary arteries and whose FFR > 0.80 and index of microcirculatory resistance (IMR) > 25. Patients will be randomly divided into the salvianolate group or the placebo group. After above evaluations, salvianolate 200 mg will be intravenously dripped immediately for the next 30 min and subsequent 7 days in the salvianolate group, and matching 0.9% normal saline will be arranged in the placebo group. IMR will be reevaluated in immediate phase after first 30 min of salvianolate or placebo treatment. The primary end point will be the IMR change in this phase, and the secondary end points will be the total ischemic burden assessed by the Seattle angina scale, quality of life scale, Holter electrocardiography, and 6-min walk test after 7 days before discharge. DISCUSSION This study will firstly clarify the improvement effect of salvianolate on coronary microcirculation and provide an effective treatment method for stable CHD patients with high FFR and myocardial microcirculatory disturbance. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR1800018772 . Registered on 9 October 2018 and updated on 2 March 2020.
Collapse
Affiliation(s)
- Zhanlu Li
- Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang, 310016, People's Republic of China
| | - Yi Luan
- Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang, 310016, People's Republic of China
| | - Min Wang
- Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang, 310016, People's Republic of China
| | - Ya Li
- Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang, 310016, People's Republic of China
| | - Xiaohua Shen
- Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang, 310016, People's Republic of China
| | - Guosheng Fu
- Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang, 310016, People's Republic of China
| | - Wenbin Zhang
- Department of Cardiology, Key Laboratory of Cardiovascular Intervention and Regenerative Medicine of Zhejiang Province, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang, 310016, People's Republic of China.
| |
Collapse
|
4
|
Chen C, Zhu P, Yu H, Huang B, Gui M, Lin X, Bai Y. Exploration of the effect of salvianolate on myocardial infarction in rats based on tandem mass tags. Eur J Pharmacol 2020; 889:173610. [DOI: 10.1016/j.ejphar.2020.173610] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 09/21/2020] [Accepted: 09/28/2020] [Indexed: 12/30/2022]
|
5
|
Ou Y, Sun SJ, Shi HM, Luo JF, Luo XP, Shen YZ, Chen YF, Fan WH, Liu HY, Shen W. Protective Effects of Salvianolate on Myocardial Injury or Myocardial Infarction after Elective Percutaneous Coronary Intervention in NSTE-ACS Patients: A Randomized Placebo-Controlled Trial. Chin J Integr Med 2020; 26:656-662. [PMID: 32572777 DOI: 10.1007/s11655-020-2728-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/24/2020] [Indexed: 12/21/2022]
Abstract
OBJECTIVE To evaluate the protective effects of salvianolate on percutaneous coronary intervention (PCI) related myocardial injury or myocardial infarction after elective PCI in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients. METHODS A total of 149 patients with NSTE-ACS who underwent elective PCI were enrolled. The patients were randomly allocated in a 1:1 ratio to the salvianolate group (74 cases) or the control group (75 cases). After exclusion criteria of coronary angiography, 60 patients with PCI therapy remained in the salvianolate group and 68 in the control group. The incidence and the severity of PCI related myocardial injury or myocardial infarction, in addition to major adverse cardiac events (MACEs) during 1 year follow-up after PCI were studied between the two groups. Multivariate logistic regression analysis was used to determine the independent factors for PCI related myocardial injury or myocardial infarction after elective PCI. RESULTS Compared with the control group, salvianolate treatment reduced the incidence of PCI related severe myocardial injury or myocardial infarction (11.7% vs. 26.5%, P=0.035). The rate of MACEs or all-cause death within 1 month or 1 year after the procedure was not significantly different between the two groups. CONCLUSIONS Periprocedural treatment with salvianolate reduces the incidence of PCI related severe myocardial injury or myocardial infarction, although it does not influence clinical prognosis. [Chinese clinical trial registry: ChiCTR1800016992].
Collapse
Affiliation(s)
- Yang Ou
- Department of Cardiovascular Disease, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Sheng-Jia Sun
- Department of Cardiovascular Disease, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Hai-Ming Shi
- Department of Cardiovascular Disease, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Jian-Feng Luo
- Department of Biostatistics, School of Public Health, Fudan University, Shanghai, 200032, China
| | - Xin-Ping Luo
- Department of Cardiovascular Disease, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Yun-Zhi Shen
- Department of Cardiovascular Disease, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Yu-Fei Chen
- Department of Cardiovascular Disease, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Wei-Hu Fan
- Department of Cardiovascular Disease, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Hong-Ying Liu
- Medical Department, Shanghai Green Valley Pharmaceutical Co., Ltd., Shanghai, 201203, China
| | - Wei Shen
- Department of Cardiovascular Disease, Huashan Hospital, Fudan University, Shanghai, 200040, China.
| |
Collapse
|
6
|
Cui H, Li XY, Gao XW, Lu X, Wu XP, Wang XF, Zheng XQ, Huang K, Liu F, Luo Z, Yuan HS, Sun G, Kong J, Du XH, Zheng J, Liu HY, Zhang WJ. A Prospective Randomized Multicenter Controlled Trial on Salvianolate for Treatment of Unstable Angina Pectoris in A Chinese Elderly Population. Chin J Integr Med 2019; 25:728-735. [DOI: 10.1007/s11655-019-2710-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/22/2019] [Indexed: 12/22/2022]
|
7
|
Norgren S, Gong XZ. Contrast-induced nephropathy-time for Western medicine and Chinese medicine to team up. Chin J Integr Med 2017; 24:3-5. [PMID: 28986808 DOI: 10.1007/s11655-017-2905-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Indexed: 10/18/2022]
Affiliation(s)
- Svante Norgren
- Children's and Women's Health Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden. .,Department of Nephrology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.
| | - Xue-Zhong Gong
- Children's and Women's Health Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.,Department of Nephrology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China
| |
Collapse
|
8
|
Gong XZ. Recent advances in Chinese medicine for contrast-induced nephropathy. Chin J Integr Med 2017; 24:6-9. [PMID: 28986810 DOI: 10.1007/s11655-017-2906-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Indexed: 11/29/2022]
Affiliation(s)
- Xue-Zhong Gong
- Department of Nephrology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.
| |
Collapse
|